Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.
Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. You are now leaving AARP.org and going to a website that is not ...